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ABSTRACT  58 
Background.  The Gly-to-Arg substitution at the 16 position (rs1042713) in the beta 2 59 
adrenoceptor (ADRB2) gene is associated with enhanced down-regulation and uncoupling of 60 
beta-2 receptors. 61 
Objectives. To undertake a meta-analysis to test the hypothesis that there is an interaction 62 
between the A allele of rs1042713 (Arg16 amino acid) and long acting beta agonist (LABA) 63 
exposure for asthma exacerbations in children. 64 
Methods.  Children with diagnosed asthma were recruited in five populations (BREATHE, 65 
GALA II, PACMAN, PAGES and PASS).  A history of recent exacerbation and asthma 66 
treatment were determined from questionnaire data. DNA was extracted and the Gly16Arg 67 
genotype determined.  68 
Results.  Data from 4226 children of white Northern European and Latino origin were 69 
analysed and the odds ratio for exacerbation increased by 1.52 [1.17, 1.99] p=0.0021 for 70 
each copy of the A allele among the 637 children treated with inhaled corticosteroids (ICS) 71 
plus LABA but not for treatment with ICS alone (n=1758), nor ICS plus leukotriene receptor 72 
antagonist (LTRA, n=354) or ICS plus LABA plus LTRA (n=569).   73 
Conclusions.  The use of LABA as “add-on controller”, but not LTRA, is associated with 74 
increased risk of asthma exacerbations in children carrying one or two A alleles at 75 
rs1042713. Prospective genotype stratified clinical trials are now required to explore the 76 
potential role of rs1042713 genotyping for personalised asthma therapy in children. 77 
Key words:  Adrenergic receptors; Asthma; Child; Disease exacerbation; Therapeutics. 78 
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KEY MESSAGE 79 
Clinical trials are required to determine whether treatment stratified by rs1042713 will 80 
reduce asthma exacerbation risk in children with one or two A alleles. 81 
82 
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CAPSULE SUMMARY 83 
This meta-analysis finds increased asthma exacerbation risk for children who carry ≥ 1 A 84 
allele of rs1042713, but only in the context of treatment with inhaled corticosteroids and 85 
long acting beta agonist.   86 
87 
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ABBREVIATIONS 88 
ADRB2 Beta 2 Adrenoceptor 89 
LABA Long Acting Beta Agonists 90 
LTRA Leukotriene Receptor Antagonist 91 
ICS Inhaled Corticosteroids 92 
MAF Minor Allele Frequency 93 
PAGES Paediatric Asthma Gene Environment Study 94 
PASS Pharmaco genetics of Adrenal Suppression with inhaled Steroid study 95 
SABA Short Acting Beta Agonists 96 
SNP Single Nucleotide Polymorphism 97 
98 
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INTRODUCTION 99 
Asthma is a common condition in children where there is heterogeneity in response to 100 
treatment with inhaled corticosteroids (ICS), long acting beta agonists (LABA) and 101 
leukotriene receptor antagonists (LTRA) (1, 2).  Some of this heterogeneity may reflect genetic 102 
variations within the population, and variants in the gene coding for the beta 2 103 
adrenoceptor (ADRB2) have been associated with increased risk for symptoms (3-5). Of 104 
particular interest is the single nucleotide polymorphism (SNP) rs1042713, a Gly to Arg 105 
amino acid substitution at the position 16 of the ADRB2 gene, which has been associated 106 
with differences in pulmonary function responsiveness to short acting beta agonists in 107 
children (6-9) and the underlying mechanism of enhanced down-regulation and uncoupling of 108 
beta-2 receptors is thought to reflect an altered response to short and long acting beta 109 
agonists (SABA and LABA).   110 
Although the SNP rs1042713 appears to alter physiological and clinical response to SABA 111 
and LABA in paediatric populations, the clinical relevance of this association remains 112 
unclear.  In two clinical trials there was no evidence for an association between the A allele 113 
of rs1042713 (Arg16 amino acid) and increased symptom score (1, 7).  There is inconsistent 114 
evidence from observational studies that this SNP may be relevant to exacerbations. In 115 
children, the homozygous G/G genotype of rs1042713 has been linked with increased risk 116 
for hospitalisation(10), reduced bronchodilator response to short acting beta agonists(9), 117 
prolonged stay in hospital (11) and intensive care unit stay (12) after presentation with acute 118 
asthma, whilst the heterozygous genotype of rs1042713 has been linked with increased risk 119 
for intubation for acute asthma (13).  Two other groups have observed associations between 120 
A/A genotype of rs1042713 and increased exacerbations among those treated with LABA (3, 4) 121 
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 but this was not confirmed in a third population(14).  These studies have also observed 122 
increased exacerbation risk (3) and poorer asthma control (4) among those children 123 
homozygous for A/A for the SNP rs1042713 in receipt of ICS (but not LABA).  In one study (3), 124 
there was evidence that concomitant LTRA treatment might negate any increased risk for 125 
exacerbation associated with LABA treatment, while those children who are homozygous for 126 
Arg16 had better asthma outcomes when treated with LTRA rather than LABA in addition to 127 
to ICS (15).  Prospective studies undertaken in adult populations have found no evidence for 128 
LABA treatment being associated with adverse outcomes when added to ICS(16-18) 129 
  130 
To better understand the interactions between the SNP rs1042713 of ADRB2 and asthma 131 
treatment, we undertook a meta-analysis of results from five previously described 132 
populations (19).  Our hypothesis was that there is an interaction between the A allele of 133 
rs1042713 (Arg16 amino acid) and treatment with LABA, but not LTRA, for asthma 134 
exacerbation risk and that this risk might be further increased by exposure to daily SABA.   135 
136 
Turner 9 
 
 
METHODS  137 
Study design.  Children with asthma were recruited to five cross-sectional studies 138 
(BREATHE, GALA II, PAGES, PACMAN and PASS).   The BREATHE and PAGES populations were 139 
recruited from primary and secondary care in Scotland, PACMAN was recruited from 140 
children attending community pharmacists in Netherlands,  GALA II recruited children in 141 
USA and Puerto Rico who had four Latino grandparents and PASS recruited children with 142 
asthma who had adrenal suppression testing in 25 hospitals across the UK.  Further details 143 
of the study population’s recruitment are presented in the Online Repository.  DNA was 144 
extracted from saliva or blood and the genotypes for rs1042713 determined.  The primary 145 
outcome was asthma exacerbation (with reference to six months in BREATHE, PAGES and 146 
PASS and 12 months in GALA II and PACMAN).  Asthma treatment was categorised thus: (i) 147 
as required (prn) SABA but no preventer treatment (ii) ICS monotherapy plus prn SABA (iii) 148 
ICS plus prn SABA and LABA (iv) ICS plus prn SABA and LTRA and (v) ICS plus prn SABA, LABA 149 
and LTRA.  As previously (5), as required SABA was categorised as at least once daily or less 150 
frequently.  Approval was obtained from medical research ethics committees from each 151 
institute prior to recruitment.  All participants gave verbal assent and parents or participants 152 
gave written consent as appropriate. 153 
Definitions of exacerbation.  For BREATHE and PAGES the definition of exacerbation was at 154 
least one of the following in the previous six months in the context of asthma symptoms: 155 
hospital admission, course of oral steroids or absence from school.  For GALA, an 156 
exacerbation was defined as at least one of the following during the previous 12 months: 157 
oral corticosteroid rescue treatment, hospitalisation or need to seek emergency asthma 158 
care.  For PACMAN, an exacerbation was defined as an asthma-related visit to emergency 159 
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department and/or prescribed a course of oral steroids in the past twelve months.  The 160 
definition of exacerbation for PASS was at least one course of rescue oral steroids in the 161 
previous six months.      162 
DNA collection, extraction and analysis. For BREATHE, PACMAN and PAGES, saliva was 163 
collected in commercially available pots (Oragene, DNA Genotech, Ontario, Canada) DNA 164 
was prepared using the Qiagen Dneasy 96 kit, and genotypes were determined in the 165 
Dundee laboratory using Taqman based allelic discrimination assays on an ABI 7700 166 
sequence detection system, as described previously(3).  For GALA II, DNA was extracted from 167 
whole blood and the Axiom® LAT1 array (World Array 4, Affymetrix, Santa Clara, CA) was 168 
used to determine genome wide-genotype data as described elsewhere(20).  For PASS, the 169 
Illumina Human OmniExpressExome-8 v1.0 chip (Illumina, San Diego, CA) was used for 170 
genotyping. 171 
Statistical analysis.  The primary outcome was recent exacerbation and this was related to 172 
genotype in logistic models.  An additive model (3) was used, i.e. a gene/dosage effect for the 173 
A allele [Arg16 aminoacid] which adjusted for confounders (i.e. gender, age, second hand 174 
smoke exposure (3)).  Each population was stratified by treatment and risk for exacerbation 175 
per genotype was calculated in each treatment group.  Daily SABA use was recorded for 176 
BREATHE, PACMAN and PAGES and here an interaction as sought for SABA treatment x 177 
genotype.  Regression analyses in GALA II included the same covariates as in the other 178 
studies, but additionally we included estimates of global African and Native American 179 
genetic ancestry to avoid confusion due to population stratification.  Standard statistical 180 
software was used (SPSS version 22.0.0.1).  The meta-analysis of data from the five 181 
populations was performed using a fixed-effect (inverse variance–weighted) model, where 182 
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the effect size estimates, β coefficients, are weighted by their estimated standard errors 183 
using GWAMA software(21). We estimated the power of the study to detect the associations 184 
with exacerbations following the methodology of Purcell et al (22). Our power calculations 185 
provide the maximal power we could obtain from the meta-analysis of the cohorts at the 186 
significance level of 5%. The odd ratios of 1.2, 1.5 and 3 were selected based on initial 187 
results from the BREATHE trial. With the exception of the ICS+LTRA treatment group, all 188 
strata were sufficiently powered to detect an odds ratio of 1.5 or above (See table I in the 189 
Online Repository) . Forest plots were generated with the package rmeta for R. A p value of 190 
<0.05 was assumed to be significant.  191 
192 
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RESULTS 193 
Study subjects 194 
Genotype, treatment and exacerbation data were available in 4226 children including 1210 195 
from BREATHE, 1171 from GALA II, 760 from PACMAN, 695 from PAGES and 390 from PASS, 196 
table I.  The Gly16Arg polymorphism was in HWE for all cohorts with the exception of 197 
BREATHE (exact test p=0.012) considered as a whole, but it was in HWE in the group of 198 
children that did not have exacerbations (p=0.624). The minor allele frequency (MAF) for 199 
GALA II was higher when compared to the three UK cohorts (0.45 vs 0.37) p=1x10-10, and 200 
intermediate for the PACMAN population. Regardless of treatment, across the five 201 
populations the additive model found an increased risk for exacerbation for each copy of 202 
the A allele amounting to 1.11 [1.01, 1.22] p=0.035, n=4226 (See table II in the Online 203 
Repository).   204 
Risk of exacerbation across maintenance treatment groups 205 
The odds ratio for exacerbation was 1.52 [1.17, 1.99] for each copy of the A allele among 206 
the 637 children treated with ICS plus LABA, table II.  The risk for exacerbation was not 207 
increased among other treatment groups, table II.  Table III presents the proportion of 208 
children with exacerbations stratified by population, treatment and genotype.  The analysis 209 
for children treated with ICS plus LABA had >90% power to detect an association with 210 
increased risk for exacerbation at the significance level of 5% (Table I in the Online 211 
Repository).  An analysis of local African ancestry at the Gly16Arg locus was undertaken in 212 
the GALA II population to examine if the number of chromosomes indicative of African 213 
ancestry at this locus was associated with increased exacerbations. There was no 214 
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association of local African ancestry with exacerbations in GALA II in the overall population 215 
(OR=1.17, 95% CI: 0.89-1.53, p=0.270) or in the group of patients treated with ICS plus LABA 216 
(OR=1.78, 95% CI: 0.58-5.49, p=0.316). 217 
Risk of exacerbation in relation to SABA use 218 
Among the 822 children in receipt of daily SABA (including 56 who were not on ICS, LABA or 219 
LTRA) there was no evidence of increased risk in the additive model (OR 1.01 [0.79, 1.31], 220 
see table III in the Online Repository)).  Among those children in receipt of ICS plus LABA 221 
there was no evidence of any additional increased risk in relation to each A allele for 222 
exacerbations among those taking daily SABA (see table IV in the Online Repository).   223 
Asthma control scores and Arg16 homozygous genotype 224 
The risk for poorly controlled asthma (as evidence by the asthma control questionnaire 6 225 
score >1.5) was increased among A/A homozygotes prescribed ICS only within the cohort 226 
PACMAN (OR 2.15) (4).  Within the PAGES population 63% (282/446) were poorly controlled 227 
(as evidenced by Children’s Asthma Control Test score <20) and there was no increase in risk 228 
for poor control for A/A homozygotes among any treatment groups.    229 
230 
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DISCUSSION 231 
Genetic epidemiology is complicated by inconsistent findings between populations.  232 
Therefore replication of findings across different populations is crucial to generalising 233 
results (23).  Associations between SNP rs1042713 and LABA and SABA treatment have been 234 
previously reported in evaluations of the first 546 children recruited to BREATHE(3) and the first 597 235 
recruited to PACMAN(4) (data from 1210 and 760 included in the present report respectively).  236 
However, the results of other studies in adults were in apparent conflict with the above 237 
observations. This meant that, prior to this study, the important clinical question of whether or not 238 
there is a need to progress to further randomised controlled trials assessing benefit with testing for 239 
SNP rs1042713 in the clinical setting had not been resolved.  This study combined data from five 240 
cohorts of children with asthma from white European and Hispanic/Latino populations to 241 
explore interactions between exposures to different asthma medications and the SNP 242 
rs1042713 for risk of asthma exacerbation.  We analysed data from 4226 children and draw 243 
three conclusions.  First, among children exposed to ICS plus LABA as dual combination 244 
therapy there was a 52% increased risk for exacerbation for each copy of the A allele.  245 
Second, the interaction between the A allele and exposure to LABA was not present when 246 
LTRA treatment was also co-prescribed as triple therapy.  Third, there was no evidence that 247 
daily SABA usage in addition to ICS plus LABA was associated with any increased further risk 248 
for exacerbation among children carrying at least one A allele.  The combined incidence of 249 
A/G heterozygous and A/A homozygous genotype is approximately 60% and these 250 
observations implicate the SNP rs1042713 as an important factor in the well-recognised 251 
heterogeneity of treatment response in children with asthma(1, 2).  This study has established 252 
the need for further prospective clinical trials where treatment is stratified by genotype to 253 
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move these observations into clinical practice in order to evaluate a more personalised 254 
approach to treatment of children with poorly controlled asthma despite treatment with 255 
inhaled corticosteroids.     256 
We observed heterogeneity between populations for the relationship between SNP 257 
rs1042713 and treatment with ICS plus LABA and risk for exacerbation with the risk being 258 
highest in GALA II and lowest in PASS.  Although this study was not designed to explain the 259 
variability between populations, there was no obvious association between the effect size 260 
for exacerbation risk associated with A allele and characteristics of the five populations; for 261 
example the children in GALA II and PASS were comparable in terms of age, sex distribution 262 
and exacerbation rate.  More children in PASS were in receipt of ICS plus LABA compared to 263 
GALA II but the hypothesis that exacerbation risk attributable to the A allele is lower for 264 
populations where LABA treatment is more prevalent is not supported by observations in 265 
the PACMAN and PAGES populations where 19% in each received LABA but the 266 
exacerbation risk associated with ICS plus LABA was 2.54 and 1.29 respectively. The 267 
heterogeneity between populations, and within populations (1, 2), might give potential insight 268 
into the pharmacogenetic mechanism(s) but also highlights the need for stratified treatment 269 
in childhood asthma.   270 
The minor allele frequency was substantially higher for children in the GALA II population 271 
compared to the three UK populations and, as suggested by previous work (18, 24), we 272 
explored the possibility that the increased exacerbation rate associated with the Arg16 273 
allele in LABA-treated GALA II subjects reflected the African ancestry associated with this 274 
allele. In our adjustment for measures of ancestry for the analyses of the Gly16Arg locus 275 
within the GALA II population we did not find significant evidence that African ancestry was 276 
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relevant to the positive correlation between minor allele frequency and prevalence of 277 
exacerbation, however our analysis was underpowered and the two-fold increase in risk 278 
which was detected might have been significant had our sample size been larger.  Our study 279 
was not designed to explore how ethnic differences might be relevant to the 280 
pharmacogenetics or treatment response to LABA and unfortunately there were insufficient 281 
numbers of children with African ancestry in the cohorts other than GALA II to further 282 
explore this intriguing hypothesis which merits focussed research in future. 283 
The pharmacogenetics of LABA and SABA are notable for the contrasting effects seen for the 284 
Gly16Arg locus on acute versus chronic SABA.  There has been considerable consistency in 285 
the observed effects of Gly16Arg on acute SABA response with many studies showing a 286 
similar direction of effect on bronchodilation (favouring Arg16)(6, 7, 11, 25, 26). A seemingly 287 
opposite effect (favouring Gly16) was seen for chronic SABA exposure and lung function and 288 
asthma control in the Beta Agonists in Mild Asthma (BAGS) (27) and Beta-Adrenergic 289 
Response by Genotype (BARGE) (28) studies and another study by Taylor et al (29).  The focus 290 
of the present study was LABA therapy but we found no evidence for either daily SABA use 291 
or the combination of daily SABA plus LABA being linked with increased exacerbation risk for 292 
children carrying Arg16 allele.  One interpretation of our findings is that the LABA caused 293 
effective adrenoceptor blockade and the “adverse” effect of LABA treatment had subsumed 294 
any “benefit” of acute SABA treatment for individuals carrying an Arg16 allele. 295 
 296 
Although we find evidence here for response to LABA therapy to be modified by the 297 
Gly16Arg locus in children, for adults this locus appears to have no effect on response to 298 
LABA therapy based on large retrospective analyses and prospective genotype-stratified 299 
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clinical trials by Bleecker (16) and the LARGE trial (18). There is evidence that the Gly16 allele 300 
might be associated with a bronchoprotective effect in association with LABA treatment (18, 301 
30).  The present study was not designed to explore the apparent inconsistency between 302 
observations in adults and children but differences in response of children and adults to 303 
LABA are well-recognised.  The addition of LABA to ICS treatment in adults with poorly 304 
controlled asthma is accepted to be superior to alternative treatments (31, 32) but in children 305 
the evidence is that LABA are no more effective that addition of LTRA or increase in ICS (1, 33).   306 
 307 
Our analysis included a relatively large number of well-characterised children with asthma 308 
from five populations and therefore any significant association is likely to be generalizable 309 
to other similar populations, perhaps aside from those where there is a higher proportion of 310 
individuals of African descent where the A allele is more prevalent.  In the literature there 311 
are apparently conflicting associations reported between variants of the SNP rs1042713 and 312 
response to treatment (3-6, 9, 11) and one explanation for this heterogeneity is that the earlier 313 
findings are based on relatively small single populations, i.e. which number less than 1000, 314 
and meta-analysis addresses the potential for false positive findings and/or associations 315 
which are idiosyncratic for one population.  This meta-analysis confirms previously reported 316 
increases in the risk for exacerbations among Arg16 homozygotes in receipt of LABA 317 
treatment (3, 4).  The present study failed to replicate previously reported associations 318 
between homozygous genotype A/A and treatment with ICS alone and increased risk for 319 
exacerbation (3) or poor asthma control (4), suggesting the possibility of false positive 320 
findings.  The magnitude of risk for exacerbation associated with ICS and LABA treatment 321 
and A allele reported in first 546 children recruited to the BREATHE cohort (3) is slightly 322 
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reduced in the larger population (2.1 versus 1.5) but remains significant across all five 323 
populations. The five populations included were heterogeneous for asthma outcomes and 324 
the results could be generalised to Western European and Hispanic/Latino populations but, 325 
given the potential for different associations between rs1042713 and asthma treatment 326 
response between different ethnic groups (26), our results may not be relevant to all 327 
populations.    328 
In our analysis we explored the possible additive effect of treatment with daily SABA and 329 
LABA for exacerbations, and we have previously reported that either treatment is associated 330 
with increased exacerbations for the BREATHE population among Arg/Arg homozygotes(5).  331 
When data were pooled there was no apparent additive effect of SABA on LABA for 332 
exacerbation risk for children with one or two Arg alleles.  These results should be treated 333 
with caution since, even with a relatively large population such as we present here, there 334 
were relatively few children with ICS plus LABA and daily SABA exposure and the analysis 335 
was probably underpowered and there may be a modest additive effect which we were not 336 
able to detect.    337 
The mechanism(s) underlying the association between the Arg16 allele  and increased 338 
exacerbation in the context of LABA treatment are thought to be mediated by enhanced 339 
agonist induced down-regulation and receptor uncoupling, resulting in subsensitivity of 340 
response (34, 35).  Our novel finding of no increased risk for exacerbation among A/A 341 
homozygotes in receipt of ICS and LABA and LTRA suggests that factors other than ADRB2 342 
down regulation are active since LABA exposure in this group of children might be expected 343 
to down regulate ADRB2.  It is likely that LTRA merely confer an additional anti-344 
inflammatory effect in individuals exposed to LABA, such that in genetically susceptible 345 
Turner 19 
 
 
patients it might be seen as a salutary effect by counteracting the response to LABA.  Where 346 
the LABA effect is negated (i.e. in Arg/Arg) the additive effect of LTRA will be more evident 347 
compared to the setting where LABA effect is more pronounced (i.e. Gly/Gly) and the 348 
additive effect of LTRA will be less evident.  Indeed in one study using AMP challenge as the 349 
primary outcome, there was better protection with ICS/LABA/LTRA as triple therapy 350 
compared to dual therapy with ICS/LABA, which was also mirrored by effects on exhaled NO 351 
and blood eosinophils, suggesting that the apparent counteracting role of LTRA may arise 352 
from the additional anti-inflammatory effects of LTRA (36). 353 
This study has a number of limitations, which should be considered when these results are 354 
interpreted.  First, the associations described here do not imply causation but the findings 355 
are consistent with the results of a small genotype stratified randomised controlled  trial, 356 
which found favourable outcomes among A/A homozygotes taking LTRA compared to LABA 357 
over a period of 12 months when used as add on therapy to ICS  (15).  Second, although we 358 
are able to be conclusive as to the nature of the relationship between exposure to LABA and 359 
A/A homozygous genotype and exacerbation, we cannot exclude the possibility that there 360 
may be a small additive relationship between SABA and LABA for exacerbation.  The 361 
relationship between LABA, SABA and exacerbations will always be a challenge to study 362 
since frequent SABA treatment is an indication for LABA therapy but our findings suggest 363 
that the magnitude of association with LABA is greater than SABA, which perhaps is not 364 
surprising given the potential impact more prolonged receptor occupancy conferred by 365 
LABA than SABA, especially in genetically susceptible individuals.  Third, more detailed 366 
genotyping of the ADRB2 locus a genome wide association study (GWAS) or haplotype 367 
analysis might have yielded additional insight into the relationship between genetic 368 
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variations of the ADRB2 but neither GWAS or haplotype data were available for all cohorts 369 
and we focussed on the SNP rs1042713 since there is a large literature which indicates that 370 
this is associated with outcomes for asthma treatment.  A fourth limitation is that we have 371 
assumed that treatment has been assigned based on the same criteria and it is possible that 372 
in some cohorts, children with more severe asthma and at increased risk for exacerbations 373 
might not have received LABA treatment but this would tend to underestimate the effect of 374 
the interaction between LABA treatment and the SNP rs1042713 for exacerbations. A fifth 375 
limitation is that rare variants were not genotyped which could also have an impact on adverse 376 
events during LABA therapy; however, these cohorts were not powered for a rare variant analysis 377 
and the rare variants identified by Ortega et al (38) occurred in the background of Gly16, not Arg16.  378 
Finally, the polymorphism Gly16Arg allele frequency was not in Hardy Weinberg Equilibrium 379 
for the whole BREATHE cohort but the consistency of the results across the cohorts suggests 380 
that the deviation within this single cohort did not substantially influence the overall results. 381 
Furthermore, Gly16Arg is an inconsistently replicated and, at best, weak locus for asthma severity 382 
so it does not seem plausible that selection for exacerbation (the primary outcome and linked to 383 
asthma severity) in this study is the cause for the deviation from HWE seen in the BREATHE cohort. 384 
Since Gly16Arg is a better established pharmacogenetic locus, a more plausible outcome which 385 
would influence deviations from HWE is exacerbations or symptoms despite frequent SABA use or 386 
LABA use, but this represents a small percentage of the BREATHE cohort (18% and 11%, 387 
respectively). 388 
In conclusion, children with asthma on ICS plus LABA were at 52% increased risk for 389 
exacerbation in the previous 6-12 months for each A allele (Arg16 amino acid) compared to 390 
G/G homozygotes (Gly16/Gly16).  Knowing that there are 1 million children in the UK with 391 
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asthma and 10% of these are prescribed LABA (3938) and 60% of these carry at least one 392 
Arg16 allele, there are approximately 60,000 children in the UK today, and approximately 393 
25,000 in the Netherlands, who might be at risk from the morbidity of exacerbation which is 394 
preventable by treatment with either no LABA or perhaps with the addition of LTRA if 395 
genotyping of rs1042713 could be made available at the point of prescribing.  Put another 396 
way, and assuming that at least one third of the UK national healthcare costs attributable to 397 
childhood asthma are due to urgent care(40, 4139, 40), stratified treatment might reduce the 398 
annual direct costs to the UK National Health Service for the management of childhood 399 
asthma exacerbations by 10% (i.e. a 50% reduction in 60% of the population).  Whilst there 400 
are no recent published costs for the management of childhood asthma, costs in the US 401 
have been estimated at $791per child per annum in 2005 (4140)  and to total £150 million in 402 
the UK in 1997 (4241).  It is thus likely that stratified treatment in childhood asthma will save 403 
tens of millions of pounds in direct healthcare costs. Not all asthmatics who inherit an A 404 
allele will experience increased morbidity with LABA treatment and this might be explained 405 
by rare variants, perhaps at the same locus (3842), pathway related variation(43), epigenetic 406 
mechanisms or treatment adherence. 407 
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Table I.  Comparison of details of children in each of the five study populations. *Dutch, Moroccan and Turkish ethnicities were considered 
Caucasian in PACMAN.  †ethnicity data were not available for all participants in PAGES. ‡daily short acting beta agonist status was not 
determined in GALA II and PASS.¶ minor allele frequency = frequency of minor allele homozygous genotype + (frequency of heterozygous 
genotype)/2  
 BREATHE 
n=1210 
GALA II 
n=1171 
PACMAN 
n=760 
PAGES 
n=695 
PASS  
n=390 
% Male (n) 60% (725) 58% (676) 63% (478) 57% (399) 56% (172) 
% Exposed to tobacco smoke at home (n) 35% (424) 21% (242) 14% (108) 21% (146) 36% (108) 
Mean age, (SD) years 9.7 (3.8) 11.9 (2.7) 8.7 (2.3)  9.8 (3.7)  11.1 (4.0)  
Recent exacerbation 44% (536) 65% (763) 10% (76) 47% (323) 75% (295) 
 
 
Ethicity 
% Caucasian  
 
No data 
0% 90%* 
(681/753) 
93%† 
(358/384) 
99% 
(388/390) 
% Hispanic 100% 0.4%  
(3/753) 
0% 0% 
% African  0% 1%     
(8/753) 
0% 0% 
% Other (including mixed) 0%  8.6% 
(61/753) 
7%  
(26/384) 
1%    
(2/390) 
Minor allele frequency¶ 0.37 0.45 0.41 0.37 0.38 
 A/A (Arg/Arg) (n) 15% (175) 20% (234) 15% (115) 14% (96) 16% (61) 
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rs1042713 genotype A/G (Arg/Gly) (n) 43% (515) 49% (579) 51% (388) 46% (321)  43% (169) 
G/G (Gly/Gly) (n) 43% (520) 31% (358) 34% (257) 40% (278)  41% (160) 
 
 
 
 
 
 
Treatment group 
% Short acting beta agonist alone 
(n) 
18% (218) 42% (490) 10% (73) 7% (51) 0% 
% Inhaled corticosteroid, ICS, (n) 58% (698) 24% (283) 63% (476) 40% (273) 7% (28) 
% ICS plus long acting beta 
agonist, LABA, (n) 
11% (138) 10% (122) 19% (147) 19% (134) 33% (96) 
%ICS plus leukotriene receptor 
antagonist, LTRA, (n 
5% (65) 15% (177) 3%   (23) 9%   (65) 8%  (24) 
% ICS plus LABA plus LTRA, (n) 8%   (91) 9% (99) 5%   (41) 24% (169) 59% (230) 
% with daily short acting beta agonist dosing, (n)    21% (250) ‡ 49% (364) 30% (209) ‡ 
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Table II.  Odds ratio for exacerbation per copy of the A allele (Arg16 amino acid). Results are from logistic regression models which adjusted for 
sex, age and exposure to second hand smoke at home. SABA=short acting beta agonist. ICS =inhaled corticosteroids. LABA= long acting beta 
agonist.  LTRA=leukotriene receptor antagonist. *There were no children in PASS on SABA alone. 
 
Treatment group 
Odds ratio [95% confidence interval] for exacerbation per A allele (referenced to none) 
BREATHE GALA II  PACMAN PAGES PASS Results from all 
cohorts combined 
Results for all 
cohorts except GALA 
II 
SABA alone  0.87 [0.54, 1.40] 
(n=218) 
1.08 [0.81,1.43] 
(n=490) 
1.07 [0.06, 20.2] 
(n=73)    
0.71 [0.18, 2.80] 
(n=51) 
* 1.01 [0.79, 1.28] 
(n=832) p=0.95 
 0.85 [0.55, 1.33] 
(n=342) p=0.49 
ICS alone 1.15 [0.92, 1.43] 
(n=698) 
1.12 [0.78,1.62] 
(n=283) 
0.83 [0.53, 1.31] 
(n=476) 
1.17 [0.80, 1.71] 
(n=273) 
4.81 [0.79, 29.33] 
(n=28)  
1.11 [0.95, 1.31]  
(n=1758) p=0.18 
 1.11 [0.94, 1.33] 
(n=1475) p=0.22 
ICS+LABA  1.52 [0.92, 2.50] 
(n=138) 
2.07 [1.03, 4.16] 
(n=122) 
2.54 [1.06, 6.06] 
(n=147) 
1.29 [0.76, 2.19] 
(n=134) 
1.21 [0.68, 2.14] 
(n=96)  
1.52 [1.17, 1.99]  
(n=637) p=0.0021 
 1.44 [1.08, 1.93] 
(n=515) p=0.01 
ICS+LTRA 1.86 [0.85, 4.08] 
(n=65) 
1.26 [0.79, 2.02]  
(n=177) 
2.10 [0.43, 10.2] 
(n=23) 
0.69 [0.34, 1.39] 
(n=65) 
0.31 [0.08, 1.18]    
(n=24) 
1.11 [0.80, 1.55] 
(n=354)  p=0.52 
 0.98 [0.61, 1.56]  
(n=177) p=0.93 
ICS+LABA+LTRA 1.03 [0.54,1.96] 
(n=91)  
0.93 [0.36,2.39] 
(n=99) 
0.23 [0.04,1.46]   
(n=41) 
0.87 [0.52, 1.45] 
(n=169) 
1.02 [0.70,1.48] 
(n=169) 
0.94 [0.73, 1.22]  
(n=569) p=0.65 
 0.95 [0.72, 1.24] 
(n=470) p=0.68 
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Table III.  The proportion (percentage) of children with exacerbations stratified by treatment class and SNP rs1042713. 
 
Treatment 
group 
BREATHE GALA II  PACMAN PAGES PASS 
AA AG GG AA AG GG AA AG GG AA AG GG AA AG GG 
SABA alone  7/29 
(24%) 
28/101 
(28%) 
25/88 
(28%) 
57/92 
(62%) 
150/241 
(62%) 
88/157 
(56%) 
0/10 
(0%) 
2/42 
(5%) 
0/21 
(0%) 
0/8 
(0%) 
5/23 
(22%) 
4/20 
(20%) 
0 0 0 
ICS alone 52/98 
(53%) 
121/296 
(41%) 
126/304 
(41%) 
43/62 
(69%) 
93/151 
(62%) 
46/70 
(66%) 
6/76 
(8%) 
24/243 
(10%) 
19/157 
(12%) 
15/38 
(40%) 
33/122 
(27%) 
35/113 
(31%) 
 1/2 
(50%) 
7/15 
(47%) 
2/11 
(18%)  
ICS+LABA  18/22 
(82% 
25/55 
(46%) 
33/61 
(54%) 
25/30 
(83%) 
43/56 
(77%) 
23/36 
(64%) 
6/20 
(30%) 
3/73 
(4%) 
4/54 
(7%) 
11/18 
(61%) 
36/64 
(56%) 
25/52 
(48%) 
 8/17 
(47%) 
25/41 
(61%)  
16/38 
(42%)  
ICS+LTRA 8/11 
(73%) 
18/26 
(69%) 
15/28 
(54%) 
22/34 
(65%) 
59/81 
(73%) 
39/62 
(63%) 
1/5 
(20%) 
3/9 
(33%) 
1/0 
(11%) 
5/11 
(46%) 
16/27 
(59%) 
17/27 
(63%) 
 2/5 
(40%) 
2/7 
(29%) 
10/12 
(83%) 
ICS+LABA+ 
LTRA 
11/15 
(73%) 
23/37 
(62%) 
26/39 
(67%) 
13/16 
(81%) 
37/50 
(74%) 
25/33 
(76%) 
0/4 
(0%) 
3/21 
(14%) 
4/16 
(25%) 
14/21 
(67%) 
58/82 
(71%) 
47/66 
(71%) 
17/35 
(49%)  
58/101 
(57%)  
48/94 
(51%) 
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ABSTRACT  58 
Background.  The Gly-to-Arg substitution at the 16 position (rs1042713) in the beta 2 59 
adrenoceptor (ADRB2) gene is associated with enhanced down-regulation and uncoupling of 60 
beta-2 receptors. 61 
Objectives. To undertake a meta-analysis to test the hypothesis that there is an interaction 62 
between the A allele of rs1042713 (Arg16 amino acid) and long acting beta agonist (LABA) 63 
exposure for asthma exacerbations in children. 64 
Methods.  Children with diagnosed asthma were recruited in five populations (BREATHE, 65 
GALA II, PACMAN, PAGES and PASS).  A history of recent exacerbation and asthma 66 
treatment were determined from questionnaire data. DNA was extracted and the Gly16Arg 67 
genotype determined.  68 
Results.  Data from 4226 children of white Northern European and Latino origin were 69 
analysed and the odds ratio for exacerbation increased by 1.52 [1.17, 1.99] p=0.0021 for 70 
each copy of the A allele among the 637 children treated with inhaled corticosteroids (ICS) 71 
plus LABA but not for treatment with ICS alone (n=1758), nor ICS plus leukotriene receptor 72 
antagonist (LTRA, n=354) or ICS plus LABA plus LTRA (n=569).   73 
Conclusions.  The use of LABA as “add-on controller”, but not LTRA, is associated with 74 
increased risk of asthma exacerbations in children carrying one or two A alleles at 75 
rs1042713. Prospective genotype stratified clinical trials are now required to explore the 76 
potential role of rs1042713 genotyping for personalised asthma therapy in children. 77 
Key words:  Adrenergic receptors; Asthma; Child; Disease exacerbation; Therapeutics. 78 
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KEY MESSAGE 79 
Clinical trials are required to determine whether treatment stratified by rs1042713 will 80 
reduce asthma exacerbation risk in children with one or two A alleles. 81 
82 
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CAPSULE SUMMARY 83 
This meta-analysis finds increased asthma exacerbation risk for children who carry ≥ 1 A 84 
allele of rs1042713, but only in the context of treatment with inhaled corticosteroids and 85 
long acting beta agonist.   86 
87 
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ABBREVIATIONS 88 
ADRB2 Beta 2 Adrenoceptor 89 
LABA Long Acting Beta Agonists 90 
LTRA Leukotriene Receptor Antagonist 91 
ICS Inhaled Corticosteroids 92 
MAF Minor Allele Frequency 93 
PAGES Paediatric Asthma Gene Environment Study 94 
PASS Pharmaco genetics of Adrenal Suppression with inhaled Steroid study 95 
SABA Short Acting Beta Agonists 96 
SNP Single Nucleotide Polymorphism 97 
98 
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INTRODUCTION 99 
Asthma is a common condition in children where there is heterogeneity in response to 100 
treatment with inhaled corticosteroids (ICS), long acting beta agonists (LABA) and 101 
leukotriene receptor antagonists (LTRA) (1, 2).  Some of this heterogeneity may reflect genetic 102 
variations within the population, and variants in the gene coding for the beta 2 103 
adrenoceptor (ADRB2) have been associated with increased risk for symptoms (3-5). Of 104 
particular interest is the single nucleotide polymorphism (SNP) rs1042713, a Gly to Arg 105 
amino acid substitution at the position 16 of the ADRB2 gene, which has been associated 106 
with differences in pulmonary function responsiveness to short acting beta agonists in 107 
children (6-9) and the underlying mechanism of enhanced down-regulation and uncoupling of 108 
beta-2 receptors is thought to reflect an altered response to short and long acting beta 109 
agonists (SABA and LABA).   110 
Although the SNP rs1042713 appears to alter physiological and clinical response to SABA 111 
and LABA in paediatric populations, the clinical relevance of this association remains 112 
unclear.  In two clinical trials there was no evidence for an association between the A allele 113 
of rs1042713 (Arg16 amino acid) and increased symptom score (1, 7).  There is inconsistent 114 
evidence from observational studies that this SNP may be relevant to exacerbations. In 115 
children, the homozygous G/G genotype of rs1042713 has been linked with increased risk 116 
for hospitalisation(10), reduced bronchodilator response to short acting beta agonists(9), 117 
prolonged stay in hospital (11) and intensive care unit stay (12) after presentation with acute 118 
asthma, whilst the heterozygous genotype of rs1042713 has been linked with increased risk 119 
for intubation for acute asthma (13).  Two other groups have observed associations between 120 
A/A genotype of rs1042713 and increased exacerbations among those treated with LABA (3, 4) 121 
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 but this was not confirmed in a third population(14).  These studies have also observed 122 
increased exacerbation risk (3) and poorer asthma control (4) among those children 123 
homozygous for A/A for the SNP rs1042713 in receipt of ICS (but not LABA).  In one study (3), 124 
there was evidence that concomitant LTRA treatment might negate any increased risk for 125 
exacerbation associated with LABA treatment, while those children who are homozygous for 126 
Arg16 had better asthma outcomes when treated with LTRA rather than LABA in addition to 127 
to ICS (15).  Prospective studies undertaken in adult populations have found no evidence for 128 
LABA treatment being associated with adverse outcomes when added to ICS(16-18) 129 
  130 
To better understand the interactions between the SNP rs1042713 of ADRB2 and asthma 131 
treatment, we undertook a meta-analysis of results from five previously described 132 
populations (19).  Our hypothesis was that there is an interaction between the A allele of 133 
rs1042713 (Arg16 amino acid) and treatment with LABA, but not LTRA, for asthma 134 
exacerbation risk and that this risk might be further increased by exposure to daily SABA.   135 
136 
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METHODS  137 
Study design.  Children with asthma were recruited to five cross-sectional studies 138 
(BREATHE, GALA II, PAGES, PACMAN and PASS).   The BREATHE and PAGES populations were 139 
recruited from primary and secondary care in Scotland, PACMAN was recruited from 140 
children attending community pharmacists in Netherlands,  GALA II recruited children in 141 
USA and Puerto Rico who had four Latino grandparents and PASS recruited children with 142 
asthma who had adrenal suppression testing in 25 hospitals across the UK.  Further details 143 
of the study population’s recruitment are presented in the Online Repository.  DNA was 144 
extracted from saliva or blood and the genotypes for rs1042713 determined.  The primary 145 
outcome was asthma exacerbation (with reference to six months in BREATHE, PAGES and 146 
PASS and 12 months in GALA II and PACMAN).  Asthma treatment was categorised thus: (i) 147 
as required (prn) SABA but no preventer treatment (ii) ICS monotherapy plus prn SABA (iii) 148 
ICS plus prn SABA and LABA (iv) ICS plus prn SABA and LTRA and (v) ICS plus prn SABA, LABA 149 
and LTRA.  As previously (5), as required SABA was categorised as at least once daily or less 150 
frequently.  Approval was obtained from medical research ethics committees from each 151 
institute prior to recruitment.  All participants gave verbal assent and parents or participants 152 
gave written consent as appropriate. 153 
Definitions of exacerbation.  For BREATHE and PAGES the definition of exacerbation was at 154 
least one of the following in the previous six months in the context of asthma symptoms: 155 
hospital admission, course of oral steroids or absence from school.  For GALA, an 156 
exacerbation was defined as at least one of the following during the previous 12 months: 157 
oral corticosteroid rescue treatment, hospitalisation or need to seek emergency asthma 158 
care.  For PACMAN, an exacerbation was defined as an asthma-related visit to emergency 159 
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department and/or prescribed a course of oral steroids in the past twelve months.  The 160 
definition of exacerbation for PASS was at least one course of rescue oral steroids in the 161 
previous six months.      162 
DNA collection, extraction and analysis. For BREATHE, PACMAN and PAGES, saliva was 163 
collected in commercially available pots (Oragene, DNA Genotech, Ontario, Canada) DNA 164 
was prepared using the Qiagen Dneasy 96 kit, and genotypes were determined in the 165 
Dundee laboratory using Taqman based allelic discrimination assays on an ABI 7700 166 
sequence detection system, as described previously(3).  For GALA II, DNA was extracted from 167 
whole blood and the Axiom® LAT1 array (World Array 4, Affymetrix, Santa Clara, CA) was 168 
used to determine genome wide-genotype data as described elsewhere(20).  For PASS, the 169 
Illumina Human OmniExpressExome-8 v1.0 chip (Illumina, San Diego, CA) was used for 170 
genotyping. 171 
Statistical analysis.  The primary outcome was recent exacerbation and this was related to 172 
genotype in logistic models.  An additive model (3) was used, i.e. a gene/dosage effect for the 173 
A allele [Arg16 aminoacid] which adjusted for confounders (i.e. gender, age, second hand 174 
smoke exposure (3)).  Each population was stratified by treatment and risk for exacerbation 175 
per genotype was calculated in each treatment group.  Daily SABA use was recorded for 176 
BREATHE, PACMAN and PAGES and here an interaction as sought for SABA treatment x 177 
genotype.  Regression analyses in GALA II included the same covariates as in the other 178 
studies, but additionally we included estimates of global African and Native American 179 
genetic ancestry to avoid confusion due to population stratification.  Standard statistical 180 
software was used (SPSS version 22.0.0.1).  The meta-analysis of data from the five 181 
populations was performed using a fixed-effect (inverse variance–weighted) model, where 182 
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the effect size estimates, β coefficients, are weighted by their estimated standard errors 183 
using GWAMA software(21). We estimated the power of the study to detect the associations 184 
with exacerbations following the methodology of Purcell et al (22). Our power calculations 185 
provide the maximal power we could obtain from the meta-analysis of the cohorts at the 186 
significance level of 5%. The odd ratios of 1.2, 1.5 and 3 were selected based on initial 187 
results from the BREATHE trial. With the exception of the ICS+LTRA treatment group, all 188 
strata were sufficiently powered to detect an odds ratio of 1.5 or above (See table I in the 189 
Online Repository) . Forest plots were generated with the package rmeta for R. A p value of 190 
<0.05 was assumed to be significant.  191 
192 
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RESULTS 193 
Study subjects 194 
Genotype, treatment and exacerbation data were available in 4226 children including 1210 195 
from BREATHE, 1171 from GALA II, 760 from PACMAN, 695 from PAGES and 390 from PASS, 196 
table I.  The Gly16Arg polymorphism was in HWE for all cohorts with the exception of 197 
BREATHE (exact test p=0.012) considered as a whole, but it was in HWE in the group of 198 
children that did not have exacerbations (p=0.624). The minor allele frequency (MAF) for 199 
GALA II was higher when compared to the three UK cohorts (0.45 vs 0.37) p=1x10-10, and 200 
intermediate for the PACMAN population. Regardless of treatment, across the five 201 
populations the additive model found an increased risk for exacerbation for each copy of 202 
the A allele amounting to 1.11 [1.01, 1.22] p=0.035, n=4226 (See table II in the Online 203 
Repository).   204 
Risk of exacerbation across maintenance treatment groups 205 
The odds ratio for exacerbation was 1.52 [1.17, 1.99] for each copy of the A allele among 206 
the 637 children treated with ICS plus LABA, table II.  The risk for exacerbation was not 207 
increased among other treatment groups, table II.  Table III presents the proportion of 208 
children with exacerbations stratified by population, treatment and genotype.  The analysis 209 
for children treated with ICS plus LABA had >90% power to detect an association with 210 
increased risk for exacerbation at the significance level of 5% (Table I in the Online 211 
Repository).  An analysis of local African ancestry at the Gly16Arg locus was undertaken in 212 
the GALA II population to examine if the number of chromosomes indicative of African 213 
ancestry at this locus was associated with increased exacerbations. There was no 214 
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association of local African ancestry with exacerbations in GALA II in the overall population 215 
(OR=1.17, 95% CI: 0.89-1.53, p=0.270) or in the group of patients treated with ICS plus LABA 216 
(OR=1.78, 95% CI: 0.58-5.49, p=0.316). 217 
Risk of exacerbation in relation to SABA use 218 
Among the 822 children in receipt of daily SABA (including 56 who were not on ICS, LABA or 219 
LTRA) there was no evidence of increased risk in the additive model (OR 1.01 [0.79, 1.31], 220 
see table III in the Online Repository)).  Among those children in receipt of ICS plus LABA 221 
there was no evidence of any additional increased risk in relation to each A allele for 222 
exacerbations among those taking daily SABA (see table IV in the Online Repository).   223 
Asthma control scores and Arg16 homozygous genotype 224 
The risk for poorly controlled asthma (as evidence by the asthma control questionnaire 6 225 
score >1.5) was increased among A/A homozygotes prescribed ICS only within the cohort 226 
PACMAN (OR 2.15) (4).  Within the PAGES population 63% (282/446) were poorly controlled 227 
(as evidenced by Children’s Asthma Control Test score <20) and there was no increase in risk 228 
for poor control for A/A homozygotes among any treatment groups.    229 
230 
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DISCUSSION 231 
Genetic epidemiology is complicated by inconsistent findings between populations.  232 
Therefore replication of findings across different populations is crucial to generalising 233 
results (23).  Associations between SNP rs1042713 and LABA and SABA treatment have been 234 
previously reported in evaluations of the first 546 children recruited to BREATHE(3) and the first 597 235 
recruited to PACMAN(4) (data from 1210 and 760 included in the present report respectively).  236 
However, the results of other studies in adults were in apparent conflict with the above 237 
observations. This meant that, prior to this study, the important clinical question of whether or not 238 
there is a need to progress to further randomised controlled trials assessing benefit with testing for 239 
SNP rs1042713 in the clinical setting had not been resolved.  This study combined data from five 240 
cohorts of children with asthma from white European and Hispanic/Latino populations to 241 
explore interactions between exposures to different asthma medications and the SNP 242 
rs1042713 for risk of asthma exacerbation.  We analysed data from 4226 children and draw 243 
three conclusions.  First, among children exposed to ICS plus LABA as dual combination 244 
therapy there was a 52% increased risk for exacerbation for each copy of the A allele.  245 
Second, the interaction between the A allele and exposure to LABA was not present when 246 
LTRA treatment was also co-prescribed as triple therapy.  Third, there was no evidence that 247 
daily SABA usage in addition to ICS plus LABA was associated with any increased further risk 248 
for exacerbation among children carrying at least one A allele.  The combined incidence of 249 
A/G heterozygous and A/A homozygous genotype is approximately 60% and these 250 
observations implicate the SNP rs1042713 as an important factor in the well-recognised 251 
heterogeneity of treatment response in children with asthma(1, 2).  This study has established 252 
the need for further prospective clinical trials where treatment is stratified by genotype to 253 
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move these observations into clinical practice in order to evaluate a more personalised 254 
approach to treatment of children with poorly controlled asthma despite treatment with 255 
inhaled corticosteroids.     256 
We observed heterogeneity between populations for the relationship between SNP 257 
rs1042713 and treatment with ICS plus LABA and risk for exacerbation with the risk being 258 
highest in GALA II and lowest in PASS.  Although this study was not designed to explain the 259 
variability between populations, there was no obvious association between the effect size 260 
for exacerbation risk associated with A allele and characteristics of the five populations; for 261 
example the children in GALA II and PASS were comparable in terms of age, sex distribution 262 
and exacerbation rate.  More children in PASS were in receipt of ICS plus LABA compared to 263 
GALA II but the hypothesis that exacerbation risk attributable to the A allele is lower for 264 
populations where LABA treatment is more prevalent is not supported by observations in 265 
the PACMAN and PAGES populations where 19% in each received LABA but the 266 
exacerbation risk associated with ICS plus LABA was 2.54 and 1.29 respectively. The 267 
heterogeneity between populations, and within populations (1, 2), might give potential insight 268 
into the pharmacogenetic mechanism(s) but also highlights the need for stratified treatment 269 
in childhood asthma.   270 
The minor allele frequency was substantially higher for children in the GALA II population 271 
compared to the three UK populations and, as suggested by previous work (18, 24), we 272 
explored the possibility that the increased exacerbation rate associated with the Arg16 273 
allele in LABA-treated GALA II subjects reflected the African ancestry associated with this 274 
allele. In our adjustment for measures of ancestry for the analyses of the Gly16Arg locus 275 
within the GALA II population we did not find significant evidence that African ancestry was 276 
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relevant to the positive correlation between minor allele frequency and prevalence of 277 
exacerbation, however our analysis was underpowered and the two-fold increase in risk 278 
which was detected might have been significant had our sample size been larger.  Our study 279 
was not designed to explore how ethnic differences might be relevant to the 280 
pharmacogenetics or treatment response to LABA and unfortunately there were insufficient 281 
numbers of children with African ancestry in the cohorts other than GALA II to further 282 
explore this intriguing hypothesis which merits focussed research in future. 283 
The pharmacogenetics of LABA and SABA are notable for the contrasting effects seen for the 284 
Gly16Arg locus on acute versus chronic SABA.  There has been considerable consistency in 285 
the observed effects of Gly16Arg on acute SABA response with many studies showing a 286 
similar direction of effect on bronchodilation (favouring Arg16)(6, 7, 11, 25, 26). A seemingly 287 
opposite effect (favouring Gly16) was seen for chronic SABA exposure and lung function and 288 
asthma control in the Beta Agonists in Mild Asthma (BAGS) (27) and Beta-Adrenergic 289 
Response by Genotype (BARGE) (28) studies and another study by Taylor et al (29).  The focus 290 
of the present study was LABA therapy but we found no evidence for either daily SABA use 291 
or the combination of daily SABA plus LABA being linked with increased exacerbation risk for 292 
children carrying Arg16 allele.  One interpretation of our findings is that the LABA caused 293 
effective adrenoceptor blockade and the “adverse” effect of LABA treatment had subsumed 294 
any “benefit” of acute SABA treatment for individuals carrying an Arg16 allele. 295 
 296 
Although we find evidence here for response to LABA therapy to be modified by the 297 
Gly16Arg locus in children, for adults this locus appears to have no effect on response to 298 
LABA therapy based on large retrospective analyses and prospective genotype-stratified 299 
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clinical trials by Bleecker (16) and the LARGE trial (18). There is evidence that the Gly16 allele 300 
might be associated with a bronchoprotective effect in association with LABA treatment (18, 301 
30).  The present study was not designed to explore the apparent inconsistency between 302 
observations in adults and children but differences in response of children and adults to 303 
LABA are well-recognised.  The addition of LABA to ICS treatment in adults with poorly 304 
controlled asthma is accepted to be superior to alternative treatments (31, 32) but in children 305 
the evidence is that LABA are no more effective that addition of LTRA or increase in ICS (1, 33).   306 
 307 
Our analysis included a relatively large number of well-characterised children with asthma 308 
from five populations and therefore any significant association is likely to be generalizable 309 
to other similar populations, perhaps aside from those where there is a higher proportion of 310 
individuals of African descent where the A allele is more prevalent.  In the literature there 311 
are apparently conflicting associations reported between variants of the SNP rs1042713 and 312 
response to treatment (3-6, 9, 11) and one explanation for this heterogeneity is that the earlier 313 
findings are based on relatively small single populations, i.e. which number less than 1000, 314 
and meta-analysis addresses the potential for false positive findings and/or associations 315 
which are idiosyncratic for one population.  This meta-analysis confirms previously reported 316 
increases in the risk for exacerbations among Arg16 homozygotes in receipt of LABA 317 
treatment (3, 4).  The present study failed to replicate previously reported associations 318 
between homozygous genotype A/A and treatment with ICS alone and increased risk for 319 
exacerbation (3) or poor asthma control (4), suggesting the possibility of false positive 320 
findings.  The magnitude of risk for exacerbation associated with ICS and LABA treatment 321 
and A allele reported in first 546 children recruited to the BREATHE cohort (3) is slightly 322 
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reduced in the larger population (2.1 versus 1.5) but remains significant across all five 323 
populations. The five populations included were heterogeneous for asthma outcomes and 324 
the results could be generalised to Western European and Hispanic/Latino populations but, 325 
given the potential for different associations between rs1042713 and asthma treatment 326 
response between different ethnic groups (26), our results may not be relevant to all 327 
populations.    328 
In our analysis we explored the possible additive effect of treatment with daily SABA and 329 
LABA for exacerbations, and we have previously reported that either treatment is associated 330 
with increased exacerbations for the BREATHE population among Arg/Arg homozygotes(5).  331 
When data were pooled there was no apparent additive effect of SABA on LABA for 332 
exacerbation risk for children with one or two Arg alleles.  These results should be treated 333 
with caution since, even with a relatively large population such as we present here, there 334 
were relatively few children with ICS plus LABA and daily SABA exposure and the analysis 335 
was probably underpowered and there may be a modest additive effect which we were not 336 
able to detect.    337 
The mechanism(s) underlying the association between the Arg16 allele  and increased 338 
exacerbation in the context of LABA treatment are thought to be mediated by enhanced 339 
agonist induced down-regulation and receptor uncoupling, resulting in subsensitivity of 340 
response (34, 35).  Our novel finding of no increased risk for exacerbation among A/A 341 
homozygotes in receipt of ICS and LABA and LTRA suggests that factors other than ADRB2 342 
down regulation are active since LABA exposure in this group of children might be expected 343 
to down regulate ADRB2.  It is likely that LTRA merely confer an additional anti-344 
inflammatory effect in individuals exposed to LABA, such that in genetically susceptible 345 
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patients it might be seen as a salutary effect by counteracting the response to LABA.  Where 346 
the LABA effect is negated (i.e. in Arg/Arg) the additive effect of LTRA will be more evident 347 
compared to the setting where LABA effect is more pronounced (i.e. Gly/Gly) and the 348 
additive effect of LTRA will be less evident.  Indeed in one study using AMP challenge as the 349 
primary outcome, there was better protection with ICS/LABA/LTRA as triple therapy 350 
compared to dual therapy with ICS/LABA, which was also mirrored by effects on exhaled NO 351 
and blood eosinophils, suggesting that the apparent counteracting role of LTRA may arise 352 
from the additional anti-inflammatory effects of LTRA (36). 353 
This study has a number of limitations, which should be considered when these results are 354 
interpreted.  First, the associations described here do not imply causation but the findings 355 
are consistent with the results of a small genotype stratified randomised controlled  trial, 356 
which found favourable outcomes among A/A homozygotes taking LTRA compared to LABA 357 
over a period of 12 months when used as add on therapy to ICS  (15).  Second, although we 358 
are able to be conclusive as to the nature of the relationship between exposure to LABA and 359 
A/A homozygous genotype and exacerbation, we cannot exclude the possibility that there 360 
may be a small additive relationship between SABA and LABA for exacerbation.  The 361 
relationship between LABA, SABA and exacerbations will always be a challenge to study 362 
since frequent SABA treatment is an indication for LABA therapy but our findings suggest 363 
that the magnitude of association with LABA is greater than SABA, which perhaps is not 364 
surprising given the potential impact more prolonged receptor occupancy conferred by 365 
LABA than SABA, especially in genetically susceptible individuals.  Third, more detailed 366 
genotyping of the ADRB2 locus  or haplotype analysis might have yielded additional insight 367 
into the relationship between genetic variations of the ADRB2 but neither GWAS or 368 
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haplotype data were available for all cohorts and we focussed on the SNP rs1042713 since 369 
there is a large literature which indicates that this is associated with outcomes for asthma 370 
treatment.  A fourth limitation is that we have assumed that treatment has been assigned 371 
based on the same criteria and it is possible that in some cohorts, children with more severe 372 
asthma and at increased risk for exacerbations might not have received LABA treatment but 373 
this would tend to underestimate the effect of the interaction between LABA treatment and 374 
the SNP rs1042713 for exacerbations. A fifth limitation is that rare variants were not 375 
genotyped which could also have an impact on adverse events during LABA therapy; however, these 376 
cohorts were not powered for a rare variant analysis and the rare variants identified by Ortega et al 377 
(38) occurred in the background of Gly16, not Arg16.  Finally, the polymorphism Gly16Arg allele 378 
frequency was not in Hardy Weinberg Equilibrium for the whole BREATHE cohort but the 379 
consistency of the results across the cohorts suggests that the deviation within this single 380 
cohort did not substantially influence the overall results. Furthermore, Gly16Arg is an 381 
inconsistently replicated and, at best, weak locus for asthma severity so it does not seem plausible 382 
that selection for exacerbation (the primary outcome and linked to asthma severity) in this study is 383 
the cause for the deviation from HWE seen in the BREATHE cohort. Since Gly16Arg is a better 384 
established pharmacogenetic locus, a more plausible outcome which would influence deviations 385 
from HWE is exacerbations or symptoms despite frequent SABA use or LABA use, but this represents 386 
a small percentage of the BREATHE cohort (18% and 11%, respectively). 387 
In conclusion, children with asthma on ICS plus LABA were at 52% increased risk for 388 
exacerbation in the previous 6-12 months for each A allele (Arg16 amino acid) compared to 389 
G/G homozygotes (Gly16/Gly16).  Knowing that there are 1 million children in the UK with 390 
asthma and 10% of these are prescribed LABA (39) and 60% of these carry at least one Arg16 391 
allele, there are approximately 60,000 children in the UK today, and approximately 25,000 in 392 
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the Netherlands, who might be at risk from the morbidity of exacerbation which is 393 
preventable by treatment with either no LABA or perhaps with the addition of LTRA if 394 
genotyping of rs1042713 could be made available at the point of prescribing.  Put another 395 
way, and assuming that at least one third of the UK national healthcare costs attributable to 396 
childhood asthma are due to urgent care(40, 41), stratified treatment might reduce the annual 397 
direct costs to the UK National Health Service for the management of childhood asthma 398 
exacerbations by 10% (i.e. a 50% reduction in 60% of the population).  Whilst there are no 399 
recent published costs for the management of childhood asthma, costs in the US have been 400 
estimated at $791per child per annum in 2005 (41)  and to total £150 million in the UK in 401 
1997 (42).  It is thus likely that stratified treatment in childhood asthma will save tens of 402 
millions of pounds in direct healthcare costs. Not all asthmatics who inherit an A allele will 403 
experience increased morbidity with LABA treatment and this might be explained by rare 404 
variants, perhaps at the same locus (38), pathway related variation(43), epigenetic 405 
mechanisms or treatment adherence. 406 
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Table I.  Comparison of details of children in each of the five study populations. *Dutch, Moroccan and Turkish ethnicities were considered 
Caucasian in PACMAN.  †ethnicity data were not available for all participants in PAGES. ‡daily short acting beta agonist status was not 
determined in GALA II and PASS.¶ minor allele frequency = frequency of minor allele homozygous genotype + (frequency of heterozygous 
genotype)/2  
 BREATHE 
n=1210 
GALA II 
n=1171 
PACMAN 
n=760 
PAGES 
n=695 
PASS  
n=390 
% Male (n) 60% (725) 58% (676) 63% (478) 57% (399) 56% (172) 
% Exposed to tobacco smoke at home (n) 35% (424) 21% (242) 14% (108) 21% (146) 36% (108) 
Mean age, (SD) years 9.7 (3.8) 11.9 (2.7) 8.7 (2.3)  9.8 (3.7)  11.1 (4.0)  
Recent exacerbation 44% (536) 65% (763) 10% (76) 47% (323) 75% (295) 
 
 
Ethicity 
% Caucasian  
 
No data 
0% 90%* 
(681/753) 
93%† 
(358/384) 
99% 
(388/390) 
% Hispanic 100% 0.4%  
(3/753) 
0% 0% 
% African  0% 1%     
(8/753) 
0% 0% 
% Other (including mixed) 0%  8.6% 
(61/753) 
7%  
(26/384) 
1%    
(2/390) 
Minor allele frequency¶ 0.37 0.45 0.41 0.37 0.38 
 A/A (Arg/Arg) (n) 15% (175) 20% (234) 15% (115) 14% (96) 16% (61) 
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rs1042713 genotype A/G (Arg/Gly) (n) 43% (515) 49% (579) 51% (388) 46% (321)  43% (169) 
G/G (Gly/Gly) (n) 43% (520) 31% (358) 34% (257) 40% (278)  41% (160) 
 
 
 
 
 
 
Treatment group 
% Short acting beta agonist alone 
(n) 
18% (218) 42% (490) 10% (73) 7% (51) 0% 
% Inhaled corticosteroid, ICS, (n) 58% (698) 24% (283) 63% (476) 40% (273) 7% (28) 
% ICS plus long acting beta 
agonist, LABA, (n) 
11% (138) 10% (122) 19% (147) 19% (134) 33% (96) 
%ICS plus leukotriene receptor 
antagonist, LTRA, (n 
5% (65) 15% (177) 3%   (23) 9%   (65) 8%  (24) 
% ICS plus LABA plus LTRA, (n) 8%   (91) 9% (99) 5%   (41) 24% (169) 59% (230) 
% with daily short acting beta agonist dosing, (n)    21% (250) ‡ 49% (364) 30% (209) ‡ 
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Table II.  Odds ratio for exacerbation per copy of the A allele (Arg16 amino acid). Results are from logistic regression models which adjusted for 
sex, age and exposure to second hand smoke at home. SABA=short acting beta agonist. ICS =inhaled corticosteroids. LABA= long acting beta 
agonist.  LTRA=leukotriene receptor antagonist. *There were no children in PASS on SABA alone. 
 
Treatment group 
Odds ratio [95% confidence interval] for exacerbation per A allele (referenced to none) 
BREATHE GALA II  PACMAN PAGES PASS Results from all 
cohorts combined 
Results for all 
cohorts except GALA 
II 
SABA alone  0.87 [0.54, 1.40] 
(n=218) 
1.08 [0.81,1.43] 
(n=490) 
1.07 [0.06, 20.2] 
(n=73)    
0.71 [0.18, 2.80] 
(n=51) 
* 1.01 [0.79, 1.28] 
(n=832) p=0.95 
 0.85 [0.55, 1.33] 
(n=342) p=0.49 
ICS alone 1.15 [0.92, 1.43] 
(n=698) 
1.12 [0.78,1.62] 
(n=283) 
0.83 [0.53, 1.31] 
(n=476) 
1.17 [0.80, 1.71] 
(n=273) 
4.81 [0.79, 29.33] 
(n=28)  
1.11 [0.95, 1.31]  
(n=1758) p=0.18 
 1.11 [0.94, 1.33] 
(n=1475) p=0.22 
ICS+LABA  1.52 [0.92, 2.50] 
(n=138) 
2.07 [1.03, 4.16] 
(n=122) 
2.54 [1.06, 6.06] 
(n=147) 
1.29 [0.76, 2.19] 
(n=134) 
1.21 [0.68, 2.14] 
(n=96)  
1.52 [1.17, 1.99]  
(n=637) p=0.0021 
 1.44 [1.08, 1.93] 
(n=515) p=0.01 
ICS+LTRA 1.86 [0.85, 4.08] 
(n=65) 
1.26 [0.79, 2.02]  
(n=177) 
2.10 [0.43, 10.2] 
(n=23) 
0.69 [0.34, 1.39] 
(n=65) 
0.31 [0.08, 1.18]    
(n=24) 
1.11 [0.80, 1.55] 
(n=354)  p=0.52 
 0.98 [0.61, 1.56]  
(n=177) p=0.93 
ICS+LABA+LTRA 1.03 [0.54,1.96] 
(n=91)  
0.93 [0.36,2.39] 
(n=99) 
0.23 [0.04,1.46]   
(n=41) 
0.87 [0.52, 1.45] 
(n=169) 
1.02 [0.70,1.48] 
(n=169) 
0.94 [0.73, 1.22]  
(n=569) p=0.65 
 0.95 [0.72, 1.24] 
(n=470) p=0.68 
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Table III.  The proportion (percentage) of children with exacerbations stratified by treatment class and SNP rs1042713. 
 
Treatment 
group 
BREATHE GALA II  PACMAN PAGES PASS 
AA AG GG AA AG GG AA AG GG AA AG GG AA AG GG 
SABA alone  7/29 
(24%) 
28/101 
(28%) 
25/88 
(28%) 
57/92 
(62%) 
150/241 
(62%) 
88/157 
(56%) 
0/10 
(0%) 
2/42 
(5%) 
0/21 
(0%) 
0/8 
(0%) 
5/23 
(22%) 
4/20 
(20%) 
0 0 0 
ICS alone 52/98 
(53%) 
121/296 
(41%) 
126/304 
(41%) 
43/62 
(69%) 
93/151 
(62%) 
46/70 
(66%) 
6/76 
(8%) 
24/243 
(10%) 
19/157 
(12%) 
15/38 
(40%) 
33/122 
(27%) 
35/113 
(31%) 
 1/2 
(50%) 
7/15 
(47%) 
2/11 
(18%)  
ICS+LABA  18/22 
(82% 
25/55 
(46%) 
33/61 
(54%) 
25/30 
(83%) 
43/56 
(77%) 
23/36 
(64%) 
6/20 
(30%) 
3/73 
(4%) 
4/54 
(7%) 
11/18 
(61%) 
36/64 
(56%) 
25/52 
(48%) 
 8/17 
(47%) 
25/41 
(61%)  
16/38 
(42%)  
ICS+LTRA 8/11 
(73%) 
18/26 
(69%) 
15/28 
(54%) 
22/34 
(65%) 
59/81 
(73%) 
39/62 
(63%) 
1/5 
(20%) 
3/9 
(33%) 
1/0 
(11%) 
5/11 
(46%) 
16/27 
(59%) 
17/27 
(63%) 
 2/5 
(40%) 
2/7 
(29%) 
10/12 
(83%) 
ICS+LABA+ 
LTRA 
11/15 
(73%) 
23/37 
(62%) 
26/39 
(67%) 
13/16 
(81%) 
37/50 
(74%) 
25/33 
(76%) 
0/4 
(0%) 
3/21 
(14%) 
4/16 
(25%) 
14/21 
(67%) 
58/82 
(71%) 
47/66 
(71%) 
17/35 
(49%)  
58/101 
(57%)  
48/94 
(51%) 
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METHODS 
BREATHE study.  This is cohort of children and young adults with doctor diagnosed asthma 
and was recruited from primary and secondary care in Tayside.  Details of enrolment have 
been presented in detail previously(1).  Individuals aged >18 years were excluded from the 
present analysis. 
GALA II study. The genes-environment and admixture in Latino Americans (GALA II) study is 
a multi-center study of children and young adults with and without asthma, and has been 
fully described previously(2). Eligibility criteria were: aged 8-21 years of age, all four 
grandparents were Latino, <10 pack-years of smoking history. Asthma was defined based on 
physician diagnosis and report of symptoms and medication use within the last 2 years.  
Individuals aged >18 year and without asthma were excluded from this analysis. Estimates 
of African, European and Native American ancestries were obtained using an unsupervised 
analysis in ADMIXTURE(3) assuming 3 ancestral populations: African, European and Native 
American. We used reference haplotypes from individuals from HapMap phase II 
(http://hapmap.ncbi.nlm.nih.gov) for the European and African components: Utah residents 
with Northern and Western European ancestry from the CEPH collection (CEU) and Yoruba 
in Ibadan, Nigeria (YRI). Native American reference population consisted of 71 Native 
American individuals genotyped at University of California San Francisco on the Axiom LAT1 
array, including 14 Zapotec, 2 Mixe, and 11 Mixtec from the southern State of Oaxaca and 
44 Nahua individuals from Central Mexico. 
PAGES study.  The Paediatric Asthma Gene Environment Study (PAGES, 
http://www.asthma-pages.com/ ) was designed to explore interactions between genetic 
variations and exposures (including medications) in children with asthma.  Children were 
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recruited from primary and secondary care.  Details of recruitment have been published 
earlier (4). Ethnicity was not identified for the initial recruits to the study but was captured 
for approximately half participants and categorised as African, Chinese, Indian, Mixed, 
Pakistani, White British or other.  
PACMAN cohort. The PACMAN study is a study of children aged 4-12 years recruited 
through community pharmacies in the Netherlands between 2009 and 2012. Details of the 
study protocol have been described elsewhere(5).  A detailed history of the subjects was 
obtained, including information on asthma symptoms, exacerbations and medication use 
over the preceding 12 months during a study visit in the community pharmacies. Ethnicity 
was categorised as African, Asian, Caucasian (Dutch, Turkish or Moroccan), Hispanic or 
Mixed.   
PASS cohort. The Pharmaco genetics of Adrenal Suppression with inhaled Steroid study is a 
cohort study designed to explore the clinical and pharmacogenomics associations between 
use of corticosteroids in children with asthma and adrenal suppression.  Assessment 
included a respiratory questionnaire, collection of blood or salvia for DNA extraction. Details 
of recruitment have been published previously(6).  Children with an Asian ancestry were 
excluded and ethnicity for those recruited was categorised as African, Caucasian or other. 
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Table I.  The power of the sample size of the five cohorts combined to detect increases in odds ratio (OR) for asthma exacerbations 
Treatment Group OR=1.2 OR=1.5 OR=3 
Short acting beta agonist alone 44% 96% 100% 
 Inhaled corticosteroid (ICS)  70% 99% 100% 
ICS plus long acting beta agonist (LABA)  36% 91% 100% 
ICS plus leukotriene receptor antagonist (LTRA) 20% 64% 100% 
ICS plus LABA plus LTRA 34% 89% 100% 
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Table II. Odds ratio for exacerbation regardless of treatment in each cohort from the additive model.  The odds ratio indicates the risk for each 
A allele of rs1042713.  The logistic regression models adjusted for age, sex and exposure to cigarette smoke. The p value for the pooled 
analysis was 0.035. 
 
 
 
  BREATHE GALA II PACMAN PAGES PASS POOLED 
Odds ratio [95% CI] 
 
1.14 [0.97, 1.34]  
n=1210 
 
1.18 [0.98, 1.41] 
n=1171 
1.00 [0.69, 1.41] 
n=760 
1.02 [0.82, 1.28] 
n=695 
1.08 [0.81, 1.43] 
n=390 
1.11 [1.01,1.22] 
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Table III.  Odds ratio (OR) and 95% confidence interval [CI] for exacerbation for each Arg16 allele compared to Gly 16 homozygotes among 
children in receipt of daily short acting beta agonist (SABA) use regardless of other treatment.  The logistic regression models adjusted for sex, 
age and exposure to cigarette smoke.  The p value for the pooled analysis was 0.91. 
 BREATHE PACMAN PAGES POOLED 
OR [95% CI]  for children 
in receipt of SABA every 
day 
1.13 [0.77, 1.65] 
n=250 
1.41 [0.83, 2.40] 
n=364 
0.69 [0.44, 1.10] 
n=208 
1.01 [0.79, 1.31] 
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Table IV.  Odds ratio (OR) and 95% confidence interval [CI] for exacerbation using the additive model (i.e. risk for each Arg16 allele compared 
to none)  among children treated with inhaled corticosteroids and long acting beta agonists for the three populations where short acting beta 
agonist (SABA) use was determined.  The logistic regression models adjusted for sex, age and exposure to cigarette smoke.  The p values for 
the pooled analysis were 0.22 and 0.038. 
 
 BREATHE PACMAN PAGES POOLED 
OR [95% CI]  for children in 
receipt of SABA every day 
1.02 [0.37, 2.81] 
n=44 
4.57 [1.40, 14.89] 
n=74 
0.89 [0.30, 2.63] 
n=47 
1.49 [0.79, 2.79] 
 
OR [95% CI]  for children in 
receipt of SABA less than once a 
day 
1.71 [0.94, 3.12] 
n=94 
0.65 [0.06, 19.51] 
n=72 
1.55 [0.80, 2.99] 
n=87 
1.59 [1.03, 2.45] 
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